Treatment of older patients with mantle-cell lymphoma

Abstract

The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse.

We investigated whether a fludarabine-containing induction regimen improved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission.

Keywords

• older patients
• mantle-cell lymphoma
• rituximab
• fludarabine
• cyclophosphamide (R-FC)
• doxorubicin
• vincristine
• prednisone (R-CHOP)